C
Circio
Circular-RNA medicines and gene-expression systems for oncology and in vivo cell therapy
About Circio
Circio Holding ASA is an Oslo, Norway clinical-stage biotechnology company developing circVec, a circular-RNA platform for durable gene expression, and therapeutic programs including cancer immunotherapy and in vivo CAR-T. Its scientific founding work is associated with CEO Dr. Erik Digman Wiklund and Dr. Thomas B. Hansen, whose research underpins the company’s circular-RNA approach. Circio’s modular platform is designed to express therapeutic molecules and support medicines for hard-to-treat solid tumors and other diseases. In 2026, the company completed major private placements and warrant exercises, including an approximately NOK 200 million raise announced in September, to accelerate its in vivo CAR-T program and strengthen the circRNA platform with runway toward 2030.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2010
- Headquarters
- Oslo, Norway
- Listing
- IPO 2016
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Innovation Norway
Series A2 investors entered at this stage
Birk Venture
Atlas Capital Markets
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Circio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Circio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.